Next Phase Newsletter

An investment bank headquartered in the US  does not act as a traditional investment bank, as the firm participates in venture capital, investing in and working with early-stage technology and life science companies with the main goal of taking the companies to public markets. The firm has also spun out and out-licensed technologies from universities and has capabilities to help with company formation, business strategy, IP, and early IPOs. The firm utilizes a sister company to further analyze company technologies and IPs. The firm can fund from $5-12M USD from Seed to Series A rounds with preference in US-based companies, though the firm is open to global companies. 
 
The firm is looking at biotech, medical devices, and diagnostics companies and is technology-agnostic. The firm generally does not look at digital health. There has been strong interest in immuno-oncology, neurology, and CNS. 
 

The firm works closely with companies and founders and will lead investment rounds. The firm typically requires taking a board or observer seat while deciding strategy, and once the company goes public, the firm will bring in a board member with expertise in the field. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A venture capital firm, founded in 2019, is a global venture capital investor. The firm specializes in early-stage medical device companies and actively leverages expertise and industry resources to support portfolio companies. The firm prefers taking a leading role in investment rounds and may seek board seats in such cases. 

The firm focuses on medical devices and is open to all subsectors and indications. The firm seeks innovative technologies, primarily investing in Class III devices, and occasionally considers Class II devices if they demonstrate significant innovation. The firm is open to working with companies at all stages, including those in the early idea phase. 

The firm prefers founding teams with strong scientific expertise and comprehensive knowledge of their respective fields. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

An early-stage venture capital firm, headquartered in the U.S., allocates roughly 40% of its investments to life sciences. The firm primarily invests from the Seed stage, with the ability to provide follow-on capital. Check sizes are flexible, typically reaching up to mid-6 figures. The firm is open to evaluating opportunities from global companies. 

The firm has broad interests in life sciences and healthcare sectors and considers all types of innovative technologies and indication/disease areas.  
 
The firm does not impose specific requirements on company structure or management teams. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

An investment holding company founded by leading European institutions has raised over €100 million from a base of more than 200 institutional and private shareholders. The firm invests from Seed to Series B stages, with a strong preference for early-stage companies and potential for follow-on funding. Check sizes can reach up to $2 million per company, with flexibility based on the stage of development. The firm is open to both leading and co-investing, and while it is primarily Europe-focused, it is increasingly pursuing U.S. opportunities. 

The firm invests across biotech, MedTech (including therapeutics, medical devices, and diagnostics), and digital health. It remains modality- and indication-agnostic, seeking opportunities with strong growth potential and technological innovation. 

There are no specific requirements for company founding teams, and the firm works closely with its portfolio companies to support their development. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A global manufacturing company, with over a century of history, is a leader in advanced materials and pressure-sensitive adhesive technologies. With a strong presence in the U.S. for many decades, it has built a reputation for innovation across industries including aerospace, electronics, healthcare, automotive, housing/construction, environmental applications, and general industry. 

In healthcare, the firm is actively seeking strategic partnerships with early-stage companies that complement its product lines. While it is open to meeting startups at the Series A stage, its focus is more on the development stage of technologies rather than funding rounds. The company has a global outlook and welcomes partnerships worldwide. 
 
The company is particularly interested in medical devices and digital health solutions. Priority technologies include sensors for applications such as injury prevention, rehabilitation for musculoskeletal disorders, stroke recovery, and neurological conditions. The company favors startups with prototypes and looks for technologies aligned with its existing products, such as flexible or stress sensors. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A venture capital firm headquartered in the U.S. invests in pre-seed, seed, and opportunistic Series A tech-bio startups across the country. With access to a strong healthcare and life sciences network, the firm connects portfolio companies with strategic partners and resources to accelerate growth. Initial checks typically range from $300K to $1M, often through syndication or co-investment. 

The firm focuses on technology-driven biotechnology companies, particularly those leveraging AI, computational biology, and machine learning to achieve breakthroughs in drug development, diagnostics, precision medicine, and other healthcare innovations. It is indication-agnostic and prioritizes startups where technology forms the core of the value proposition and enables scalable impact. 

The firm does not enforce rigid requirements on company structure or team experience, instead seeking strong technical foundations, visionary leadership, and a clear path to commercialization. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A venture capital firm invests in transformative mental health deep tech, including psychedelics and neurotechnology. The firm invests in Pre-Seed, Seed, and Series A companies, aiming to bridge the Series A funding gap and democratize access to frontier modalities at scale. Typical initial investments range from $250,000 to $2 million, with the possibility of follow-on funding. The firm is open to both leading and co-investing in deals, and may take board seats or observer roles on a case-by-case basis. It maintains a global investment scope and is not limited to opportunities within the U.S. 

The firm focuses on transformative technologies that address mental health challenges. Areas of particular interest include psychedelic medicines, especially non-hallucinogenic neuroplastogens (notably NCEs), and short-duration psychedelic compounds aligned with the Spravato medical model. It also invests in digital therapeutics and neurotechnology designed for mental health applications. While the firm is open to early-phase companies, it has a preference for those with strong IP and patent portfolios. It looks for innovations that can make a significant impact on mental health treatments and patient outcomes and places a strong emphasis on ethical conduct. 

The firm does not have strict requirements for founding teams. Its management team, composed of startup founders and operators, provides extensive support to portfolio companies. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology